Tag
This article reviews how non-alpha IL2 receptor agonist pegenzileukin can counteract CD8 T-cell exhaustion, a key mechanism in CAR T-cell (CART19) therapy failure in relapsed/refractory large B-cell lymphoma, enhancing therapeutic efficacy
Rapid and excessive expansion of ciltacabtagene autoleucel (cilta-cel) CAR T-cells associates with delayed neurotoxicity in relapsed/refractory multiple myeloma, with absolute lymphocyte count serving as a practical biomarker to guide early
Lisocabtagene maraleucel shows sustained high remission rates and a favorable long-term safety profile in patients with heavily pretreated follicular lymphoma after three years of follow-up, including high-risk subgroups.
This study assesses medium-term cognitive changes in CNS lymphoma patients treated with CAR T-cell therapy, revealing cognitive stability or improvement up to 12 months post-treatment, despite initial neurotoxicity risks.
A pooled analysis of REPRIME-FIL and CART-SIE studies shows CAR T-cell therapy significantly improves overall survival in relapsed/refractory primary mediastinal B-cell lymphoma compared to traditional salvage treatments including ASCT.
This study elucidates the incidence and characteristics of respiratory viral infections (RVIs) within 100 days following hematopoietic cell transplant and CAR T-cell therapy, highlighting SARS-CoV-2 as the predominant pathogen and identifyi
T-cell lymphomas after CAR T-cell therapy are exceedingly rare but significant. This article reviews incidence, mechanisms, diagnostic challenges, and clinical implications to guide vigilance without overshadowing CAR T-cell therapy’s
Lisocabtagene maraleucel demonstrates durable five-year survival and potential cure in relapsed/refractory large B-cell lymphoma, with manageable long-term safety, based on data from the TRANSCEND NHL 001 trial and its long-term follow-up.
Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and saf
Arlocabtagene autoleucel (arlo-cel) is a novel GPRC5D-targeted CAR T-cell therapy showing promising efficacy and manageable safety in patients with relapsed/refractory multiple myeloma heavily pretreated with standard regimens, including pr
A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.
CAR T cells targeting the CA19-9 glycan show potent, specific anti-tumor activity in pancreatic and various gastrointestinal cancers, providing new avenues for immunotherapy of hard-to-treat solid tumors.
This article explores how T-cell immunosenescence impairs the efficacy of CD19 CAR T-cell therapy in chronic lymphocytic leukemia, highlighting potential therapeutic strategies to overcome this barrier.
TP53-mutant clonal hematopoiesis in CAR T-cell recipients is linked to a pro-inflammatory state, cytopenias, and worse survival, highlighting the importance of tailored monitoring strategies in this high-risk group.
Bispecific anti-BCMA/GPRC5D CAR T cells demonstrate high response rates and manageable safety in patients with relapsed/refractory multiple myeloma complicated by extraosseous extramedullary disease, a group with historically poor outcomes.
This study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating a
A phase 1 trial of ultralow-dose IL-10–expressing CD19 CAR T cells in 13 patients with R/R DLBCL reported a 92.3% objective response rate with manageable safety.
This study highlights how linperlisib, a PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell efficacy in T-ALL by preventing T cell exhaustion via suppression of the EGR1/DUSP2 pathway, improving anti-leukemic activity and persistence.
A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.
Anti-CD117 CAR T-cell therapy demonstrated potent elimination of malignant mast cells in preclinical models of advanced systemic mastocytosis, offering a potential new treatment approach for this aggressive disorder.
